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The field of photomedicine made
tremendous progress at the beginning
of the 20th century, owing to helio-
therapy as well as to phototherapy
of tuberculosis and the prevention
of rickets by artificial light sources. In
large part, these advances required the
expertise of both laboratory scientists
and clinicians.
In 1896, modern phototherapy
began with Niels Finsen, the father of
modern UV therapy. Aware of the
bacteria-destroying effects of sunlight,
he developed a ‘‘chemical rays’’ lamp
(a focusable carbon-arc torch), with
which he treated over 800 patients
with lupus vulgaris in his Phototherapy
Institute in Copenhagen. Eighty percent
were cured, and Finsen’s fame spread
quickly (Finsen, 1896; Finsen and
Forchhammer, 1904). He was
awarded the nobel prize in Medicine
in 1903, ‘‘in recognition of treatment
of lupus vulgaris, with concentrated
light rays’’. So far, this is the only
nobel prize ever awarded for photo-
medicine. Suffering from debilitating
Pick’s disease, he was too ill to travel to
Stockholm to receive his Prize. Finsen’s
work led to the founding of the
so-called ‘‘School of the Sun’’ in the
Swiss Alps for tuberculosis patients
(Roelandts, 2005).
In 1923, Goeckerman (1925)
introduced his regime (artificial broad-
band UVB plus coal tar) for psoriasis
and published his first results in 1925.
This treatment became very popular,
particularly in the United States, and it
was used for decades to treat psoriasis.
Later, Ingram (1953) combined this
regime with dithranol in the United
Kingdom. Amazingly, neither of
these quite effective phototherapeutic
approaches for psoriasis were in use in
central Europe. Rather, broadband
UVB on its own was quite popular.
This therapy was originally proposed in
the 1960s by Wiskemann (1963) in
Hamburg, who constructed a photo-
therapy system utilizing Osram Ultra-
vitalux lamps and another using
fluorescent UVB tubes.
Photochemotherapy dates back to
ancient times. As far back as 2,000
B.C., Indian and Egyptian healers used
the pigment-stimulating properties
of the psoralen-containing Bavachee
plants (Psoralea corylifolia) and Ammi
majus, respectively, to treat vitiligo
(Pathak and Fitzpatrick, 1992).
Modern photochemotherapy was
born in 1947 when the active ingredi-
ents of Ammi majus, 8-methoxy-
psoralen (methoxsalen; 8-MOP) and
5-methoxypsoralen (bergapten; 5-MOP),
were isolated (Fahmy et al., 1947;
Fahmy and Abu-Shady, 1948), and
the first trials with 8-MOP and sun
exposure were performed in vitiligo
patients by El-Mofty (1948) in Egypt.
The first oral use of 8-MOP to
treat psoriasis was reported in 1967
at the 21st American Academy of
Dermatology Meeting (Allyn, 1962).
In 1972, in Germany, Mortazawi
(1972) used blacklight UVA tubes in a
total-body-irradiation unit with topical
8-MOP to treat psoriasis. However, the
UVA output of these tubes was
insufficient for clinical efficacy when
8-MOP was administered orally.
In the 1970s, a cooperation of
lighting engineers, photophysicists,
and dermatologists led to the develop-
ment of a high-intensity UVA source.
These UVA irradiators made oral
psoralen photochemotherapy possible.
The pivotal publication of Parrish et al.
(1974) reported the use of this new type
of UVA tube in combination with oral
8-MOP to treat psoriasis. It proved to
be much more effective than the treat-
ment with blacklight lamps. Fitzpatrick
coined the term ‘‘PUVA’’ as an
acronym for ‘‘Psoralen plus UVA’’.
The effectiveness of PUVA was con-
firmed by well-controlled clinical
trials in thousands of patients (Wolff
et al., 1976). The classic multicenter
studies, the US Cooperative Clinical
Trial (Melski et al., 1977), and the
European PUVA study (Henseler et al.;
1981) paved the way for the wide-
spread use of PUVA in psoriasis.
Somewhat later a combination of
oral retinoids and PUVA contributed
to greater effectiveness and long-term
safety of PUVA (Ho¨nigsmann and
Wolff, 1989). A variant of PUVA origi-
nated as early as 1976 in Scandinavia
by the use of trimethylpsoralen
(trisoralen) baths and subsequent UVA
exposure (also called bath PUVA)
(Fischer and Alsins, 1976); bath-water
delivery is still in use owing to the
absence of systemic photosensitization
and the lack of gastrointestinal and
potential ocular effects, which oral
8-MOP is known to produce. How-
ever, probably owing to logistic
problems, bath PUVA has not gained
popularity among physicians and
patients as compared with the oral
form.
Since its introduction, oral PUVA has
shown excellent treatment results in a
considerable number of other derma-
toses, such as vitiligo, mycosis
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fungoides, and atopic dermatitis, and
as a preventive therapy in photo-
dermatoses. In fact, PUVA sparked a
whole new series of discoveries such
as the high-intensity UV source now
known as narrowband UVB (NB-UVB),
and later the UVA1 source (340–
400 nm) (see below).
Parrish and Jaenicke (1981) defined
the action spectrum for psoriasis with
a peak at 313 nm. This led to the
discovery of NB-UVB (311–313 nm)
irradiation, which, being more effica-
cious, has largely replaced broadband
UVB as the first-line therapy for psori-
asis. The first commercially produced
lamps at this wavelength became
available in the 1980s. van Weelden
et al. (1988) in the Netherlands and
Green et al. (1988) in Scotland demon-
strated in 1984 the clinical efficacy of
NB-UVB in psoriasis. As it was shown
to be more effective than broadband
UVB, it was increasingly used to treat
various skin disorders worldwide; its
adoption was also encouraged by its
ease of use and its much lower risk of
photocarcinogenicity (Hearn et al.,
2008; Stern, 2012).
In 1992, UVA1 (340–400 nm) was
introduced first for the treatment of
atopic dermatitis by Jean Krutmann’s
group. UVA1 penetrates deeper than
UVA2 (320–340 nm); thus it is able to
reach deep dermal components of the
skin (Krutmann et al., 1992). A few
studies with small numbers of patients
showed efficacy in some other derma-
toses such as localized scleroderma,
urticaria pigmentosa, and mycosis
fungoides. The published evidence
on how best to use UVA1 and its
dosimetry remains limited and awaits
further study. UVA1 is effective in
various diseases, but it appears to be
the first-line phototherapy for some
types of sclerosing diseases such as
morphea (Kroft et al., 2008).
In the early 1980s, a new form
of phototherapy, extracorporeal photo-
chemotherapy (photopheresis, or ECP),
was introduced by Edelson et al. (1987)
for the palliative treatment of erythro-
dermic cutaneous T-cell lymphoma
(CTCL). Its efficacy was confirmed
later by several uncontrolled clinical
trials and approved as a device in 1988
by the Food and Drug Administration
to treat this disease. In 1994, at the
International Consensus Conference
on Staging and Treatment Recommen-
dations for CTCL, ECP was recom-
mended as the first-line of treatment
for patients with erythrodermic CTCL
(Trautinger et al., 2006).
Meanwhile, ECP also has an impor-
tant role in the treatment of chronic graft
versus host disease (GVHD) after allo-
geneic bone marrow transplantation,
with excellent response rates (Greinix
et al., 1998); positive results have also
been published for acute GVHD
(Greinix et al., 2006). ECP has also
been used in several other autoimmune
diseases, including systemic sclerosis
(Knobler et al., 2006), in acute allograft
rejection among cardiac, lung, and renal
transplant recipients, and in patients
with Crohn’s disease, with some
success (Dall’Amico and Murer, 2002).
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